Applied Therapeutics (NASDAQ:APLT – Get Free Report) and Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.
Risk & Volatility
Applied Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.
Profitability
This table compares Applied Therapeutics and Ligand Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Applied Therapeutics | N/A | -340.84% | -175.00% |
| Ligand Pharmaceuticals | 20.27% | 5.22% | 2.74% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Applied Therapeutics | $1.00 million | 15.86 | -$105.62 million | ($0.10) | -1.03 |
| Ligand Pharmaceuticals | $268.09 million | 22.28 | $124.45 million | $2.24 | 133.35 |
Ligand Pharmaceuticals has higher revenue and earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and price targets for Applied Therapeutics and Ligand Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Applied Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| Ligand Pharmaceuticals | 0 | 1 | 8 | 0 | 2.89 |
Applied Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Ligand Pharmaceuticals has a consensus price target of $355.38, indicating a potential upside of 18.97%. Given Applied Therapeutics’ higher possible upside, research analysts clearly believe Applied Therapeutics is more favorable than Ligand Pharmaceuticals.
Summary
Ligand Pharmaceuticals beats Applied Therapeutics on 11 of the 14 factors compared between the two stocks.
About Applied Therapeutics
Applied Therapeutics is a biotechnology company focused on developing small-molecule medicines for rare metabolic and other serious diseases. Founded in 2016, the company is based in New York and was founded by Shoshana Shendelman, who has served as its chief executive officer. The company’s pipeline has centered on govorestat, an investigational inhibitor of the enzyme aldose reductase. Applied Therapeutics has studied the drug in conditions including classic galactosemia, SORD deficiency and PMM2-CDG, disorders that can affect multiple body systems and have limited treatment options.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
